Nippon India Pharma Fund
Nippon India Mutual Fund · Sectoral/Thematic · Regular plan, growth option
NAV (₹), 1 Oct 2026
558.2323
1-day change
-0.29%
1Y return
11.4%
3Y CAGR
16.6%
5Y CAGR
12.5%
Max drawdown, 5Y
−19.7%
NAV history month-end NAV, ₹ · 3 Apr 2006 to 1 Oct 2026
Returns vs Sectoral/Thematic median (259 schemes) and “Healthcare & pharma” median (19)
| Period | Scheme | Category median | Healthcare & pharma median |
|---|---|---|---|
| 1 month | -3.0% | -5.4% | -3.2% |
| 3 months | 0.6% | -3.1% | 2.7% |
| 6 months | 14.4% | 8.5% | 21.0% |
| Year to date | 9.6% | -2.6% | 16.3% |
| 1 year | 11.4% | 0.0% | 16.0% |
| 3 years (CAGR) | 16.6% | 11.7% | 19.2% |
| 5 years (CAGR) | 12.5% | 10.6% | 13.7% |
| 7 years (CAGR) | 21.9% | 15.7% | 23.7% |
| 10 years (CAGR) | 14.5% | 13.3% | 13.4% |
| Since first NAV (CAGR) | 17.5% | – | – |
“Healthcare & pharma” is MFIC's grouping of Sectoral/Thematic schemes by the theme or index in their names, not an AMFI category.
Rolling returns every business-day start date
| Measure | Scheme | Category median |
|---|---|---|
| 1Y rolling median | 13.9% | 9.8% |
| 3Y rolling median | 21.0% | 15.6% |
| 3Y rolling worst | -2.3% | 0.6% |
| 3Y periods positive | 97% | 100% |
| 3Y periods ahead of benchmark | 68% | 71% |
| 5Y rolling median | 18.2% | 14.2% |
| 5Y rolling worst | -0.8% | 0.3% |
| 5Y periods ahead of benchmark | 58% | 70% |
Benchmark: Nifty 500 (proxy: Motilal Oswal Nifty 500 Index Fund, price return).
Risk 36 months, monthly returns, Rf 6.5%
| Measure | Scheme | Category median |
|---|---|---|
| Standard deviation (ann.) | 14.8% | 16.7% |
| Sharpe ratio | 0.77 | 0.34 |
| Sortino ratio | 1.26 | 0.51 |
| Beta | 0.69 | 0.96 |
| Alpha (ann.) | 9.0% | 2.3% |
| Upside capture | 103.94 | 103.56 |
| Downside capture | 66.01 | 96.87 |
Drawdowns peak-to-trough falls in NAV
| Measure | Scheme | Category median |
|---|---|---|
| Maximum drawdown, full history | −47.4% | −23.7% |
| Maximum drawdown, last 10Y | −21.4% | −39.3% |
| Maximum drawdown, last 5Y | −19.7% | −22.8% |
| Current drawdown | −3.9% | −8.8% |
| Recovery time of worst fall | 301 days | – |
Longer histories include more crises, so compare the 5Y and 10Y figures across schemes of different ages.
Direct or Regular for this scheme?
The Regular plan's expense ratio is 1.84% a year and the Direct plan's 1.00%, a gap of 0.84%; over the last 3 years the Direct plan returned 1.05 percentage points a year more. On a ₹25,000 monthly SIP for 20 years (illustration at 12% a year before costs) the gap adds up to about ₹19,43,604.
With the Regular plan, that cost pays a distributor to help you plan, choose and review funds, and stay invested when markets fall. Whether it is worth it depends on how much of that you will do yourself.
TER: AMFI TER disclosure. Returns: AMFI NAVs. Illustration, not a guaranteed saving or return.
Fund managers and scheme facts Scheme Summary Document via AMFI
| Fund manager | Role | Managing since |
|---|---|---|
| Sailesh Raj Bhan | Primary | 1 Jun 2004 |
Objective: The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. There is no assurance that the investment objective of the Scheme will be achieved.
Stated asset allocation: Equity and Equity related Instruments of companies in Pharma Sector – 80%-100%, Equity and Equity Related securities of companies other than those engaged in pharma sector - 0% - 20%, Debt Securities & Money Market instruments - 0% - 20%, & Units issued by REITs and InvITs – 0%-10%
Benchmark (tier 1): BSE Healthcare TRI
Exit load: 1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter.
Minimum application: ₹5,000
Allotment date: 5 Jun 2004
Documents: Scheme Information Document · Scheme Summary Document. Read the scheme documents before investing.
Cost, size and riskometer as disclosed to AMFI
| Measure | Scheme | Category median |
|---|---|---|
| Expense ratio (TER), Regular plan | 1.84% | 2.38% |
| AUM, whole scheme (₹ crore) | 9,166 | 1,245 |
| Riskometer | Very High | – |
TER: AMFI, TER of MF Schemes. AUM and riskometer: AMFI, Fund Performance, 30 Sep 2026.
Official benchmark and category consistency
| Measure | Scheme | Benchmark / category |
|---|---|---|
| Return, 1 year (AMFI) | 12.9% | 16.8% TRI |
| Return, 3 years (AMFI) | 16.6% | 21.3% TRI |
| Return, 5 years (AMFI) | 12.7% | 14.6% TRI |
| Month-ends above category median (3Y CAGR) | 54% | 53% median |
| Month-ends in category top quartile (3Y) | 38% | 24% median |
| 7Y rolling CAGR, median (monthly windows) | 15.5% | 13.5% median |
Official benchmark: BSE Healthcare TRI (total return index, as published by AMFI). Category consistency: last 10 years of month-ends, Sectoral/Thematic Regular plans; how it is calculated.
Calendar-year returns NAV change from 31 Dec to 31 Dec
| Year | Scheme | Nifty 500 proxy | Difference |
|---|---|---|---|
| 2026 YTD | 9.6% | -7.8% | +17.3% |
| 2025 | -3.3% | 7.7% | −11.0% |
| 2024 | 34.0% | 15.6% | +18.4% |
| 2023 | 39.2% | 26.5% | +12.6% |
| 2022 | -9.9% | 3.8% | −13.7% |
| 2021 | 23.9% | 30.6% | −6.7% |
| 2020 | 66.4% | 17.2% | +49.2% |
| 2019 | 1.7% | n/a | – |
| 2018 | 3.6% | n/a | – |
| 2017 | 7.6% | n/a | – |
Benchmark proxy: Motilal Oswal Nifty 500 Index Fund (Direct plan NAV, price return), which carries its own costs. The first year starts from the first 31 December in the scheme's history.
Monthly SIP of ₹10,000 first business day of each month, ending 1 Oct 2026
| Period | Invested | Value | XIRR |
|---|---|---|---|
| 1 year | ₹1,20,000 | ₹1,28,225 | 12.9% |
| 3 years | ₹3,60,000 | ₹4,22,838 | 10.7% |
| 5 years | ₹6,00,000 | ₹8,85,419 | 15.6% |
| 10 years | ₹12,00,000 | ₹29,73,675 | 17.3% |
Uses this plan's NAVs; ignores stamp duty, exit loads and taxes. One historical path only — the interactive SIP analyzer shows outcomes across every start date.
Scheme facts
Category: Sectoral/Thematic
Plan / option: Regular · Growth
AMFI scheme code: 102431
ISIN: INF204K01968
First NAV in MFIC data: 3 Apr 2006
History: 20.5 years
Portfolio holdings: see the scheme's monthly portfolio disclosure on the fund house website
Schemes that behaved similarly correlation of monthly returns, last 5 years
| Scheme | Category | Correlation | 3Y CAGR |
|---|---|---|---|
| Aditya Birla Sun Life Pharma and Healthcare Fund | Sectoral/Thematic | 0.98 | 18.5% |
| Tata India Pharma & Healthcare Fund | Sectoral/Thematic | 0.97 | 16.5% |
| Mirae Asset Healthcare Fund | Sectoral/Thematic | 0.97 | 20.0% |
| UTI - Healthcare Fund | Sectoral/Thematic | 0.97 | 21.4% |
| HDFC Pharma and Healthcare Fund | Sectoral/Thematic | 0.96 | 28.6% |
| ICICI Prudential Healthcare Fund | Sectoral/Thematic | 0.96 | 20.1% |
Questions about Nippon India Pharma Fund
- What is the latest NAV of Nippon India Pharma Fund?
- The NAV of the Regular plan (growth option) was ₹558.2323 on 1 Oct 2026, as published by AMFI.
- Which category is Nippon India Pharma Fund in?
- It is classified as Sectoral/Thematic in AMFI's daily NAV file; a Sectoral/Thematic scheme invests at least 80% in one sector or theme. MFIC compares it with 259 Sectoral/Thematic schemes (Regular plans).
- What returns has Nippon India Pharma Fund delivered?
- Over one year the NAV changed by 11.4%. The 3-year CAGR is 16.6% (category median 11.7%) and the 5-year CAGR is 12.5% (category median 10.6%). Returns are after expenses and before tax. Past performance may or may not be sustained in future.
- How consistent have its 3-year returns been?
- Measuring a 3-year CAGR from every business day in its history, the median was 21.0%, the lowest was -2.3%, and 97% of 3-year periods ended with a gain. It was ahead of Nifty 500 (index-fund proxy) in 68% of those periods.
- What was the largest fall in Nippon India Pharma Fund's NAV?
- The largest peak-to-trough fall in its available history was 47.4%; within the last five years it was 19.7% (category median 22.8%).
- How volatile is Nippon India Pharma Fund?
- Its annualised standard deviation of monthly returns over the last 36 months is 14.8%, which is below the Sectoral/Thematic category median of 16.7%.
- What would a monthly SIP in Nippon India Pharma Fund have grown to?
- A SIP of ₹10,000 on the first business day of each month for the last 5 years (60 instalments, ₹6,00,000 invested) would have been worth about ₹8,85,419 on 1 Oct 2026, an annualised return (XIRR) of 15.6%. This uses the Regular plan's NAVs, ignores taxes and exit loads, and past performance may or may not be sustained in future.
- What is the expense ratio (TER) of Nippon India Pharma Fund?
- The total expense ratio of the Regular plan is 1.84% a year, as disclosed to AMFI (median of Sectoral/Thematic Regular plans: 2.38%). It is already deducted from the NAV, so every return shown is after expenses.
- How large is Nippon India Pharma Fund?
- Assets under management of the whole scheme were ₹9,166 crore on 30 Sep 2026, as published by AMFI.
- What is the riskometer level of Nippon India Pharma Fund?
- AMFI lists the scheme's riskometer as “Very High”, and its benchmark's as “Very High”. The riskometer is a label of potential risk set under SEBI rules, not a forecast.
- What is the benchmark of Nippon India Pharma Fund and how has it compared?
- Its official benchmark is the BSE Healthcare TRI. Over 3 years AMFI reports a return of 16.6% for this plan against 21.3% for the benchmark total return index; over 5 years 12.7% against 14.6%. Past performance does not indicate future results.
- How often has Nippon India Pharma Fund beaten its category?
- At 54% of the 120 month-ends compared over the last 10 years, its 3-year return was above the median of Sectoral/Thematic schemes (Regular plans); it was in the top quarter at 38% of them. A typical scheme would show about 50%.
- Who manages Nippon India Pharma Fund?
- According to its Scheme Summary Document, Nippon India Pharma Fund is managed by Sailesh Raj Bhan (since 1 Jun 2004).
- What is the exit load of Nippon India Pharma Fund?
- As stated in its scheme documents: 1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter. Check the latest Scheme Information Document before investing, as loads can change.
- What is the minimum investment in Nippon India Pharma Fund?
- The minimum application amount is ₹5,000. SIP details: SIP - Rs.100/- per month (minimum 60 months) Rs.500/- per month (minimum 12 months) Rs.1000/- per month (minimum 6 months) Rs. 500/- per quarter (minimum 12 quarters) Rs.1500/- per quarter (minimum 4 quarters) Rs. 5000/- per year (minimum 2 years) SWP - 500 STP - Daily- Minimum of Rs. 100 Weekly / Fortnight / Monthly option - Rs. 1000 Quarterly - Rs. 3000 Capital Appreciation Monthly/ Quarterly - Rs. 500.
- What is the difference between the Direct and Regular plans?
- Both plans hold the same portfolio; the Regular plan includes distribution costs in its expense ratio. Over one year the Direct plan's NAV changed by 12.4% and the Regular plan's by 11.4%. The Regular plan includes the services of a distributor.
Reviewing your own mutual fund portfolio?
Integrato's team can walk you through how your current schemes have behaved, using the same data shown here. Integrato is an AMFI-registered Mutual Fund Distributor.
Follow Nippon India Pharma Fund by email
Every Monday: this scheme's NAV, 1-month and 1-year return beside its category median, 3-year CAGR and how far it is below its peak. Add more schemes from their pages or from your MFIC watchlist. Free; unsubscribe from any email.
Data & disclosure. Source: AMFI daily NAV file and historical NAVs via mfapi.in; calculations by MFIC, as of 1 Oct 2026. Category medians use Regular plans in the same AMFI category. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance may or may not be sustained in future. This page is for research and education only and is not investment advice or a recommendation to buy, sell or hold any scheme. Integrato Financial Services Pvt. Ltd. is an AMFI-registered Mutual Fund Distributor (ARN-173155). Methodology.